tradingkey.logo
tradingkey.logo
Suchen

Bioventus Inc

BVS
Zur Watchlist hinzufügen
10.480USD
+0.630+6.40%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
703.18MMarktkapitalisierung
24.52KGV TTM

mehr Informationen über Bioventus Inc Unternehmen

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

Bioventus Inc Informationen

BörsenkürzelBVS
Name des UnternehmensBioventus Inc
IPO-datumFeb 11, 2021
CEOClaypoole (Robert E)
Anzahl der mitarbeiter930
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 11
Addresse4721 Emperor Boulevard, Suite 100
StadtDURHAM
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl27703
Telefon19194746700
Websitehttps://www.bioventus.com/
BörsenkürzelBVS
IPO-datumFeb 11, 2021
CEOClaypoole (Robert E)

Führungskräfte von Bioventus Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
108.72K
+29.69%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
32.28K
--
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Katrina Church, J.D.
Ms. Katrina Church, J.D.
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
--
--
Mr. William A. (Bill) Hawkins, III
Mr. William A. (Bill) Hawkins, III
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Guy Paul Nohra
Mr. Guy Paul Nohra
Independent Director
Independent Director
--
--
Marty Sutter ,
Marty Sutter ,
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Susan M. Stalnecker
Ms. Susan M. Stalnecker
Independent Director
Independent Director
138.24K
+23.35%
Mr. Guido J. Neels
Mr. Guido J. Neels
Independent Director
Independent Director
117.52K
+27.47%
Mr. John A. Bartholdson
Mr. John A. Bartholdson
Independent Director
Independent Director
111.90K
+28.85%
Mr. Patrick J. (Pat) Beyer
Mr. Patrick J. (Pat) Beyer
Independent Director
Independent Director
108.72K
+29.69%
Mr. Philip G. Cowdy
Mr. Philip G. Cowdy
Independent Director
Independent Director
32.28K
--
Mr. Anthony D'adamio, J.D.
Mr. Anthony D'adamio, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Bioventus Inc?

Die fünf größten Anteilseigner von Bioventus Inc sind: Ms. Susan M. Stalnecker

Wie viele Institutionen halten Anteile an Bioventus Inc (BVS)?

Mit Stand vom 2026Q1 halten 339 Institutionen Anteile an Bioventus Inc, mit einem Gesamtmarktwert von etwa 52.51M, was 77.51% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -10203484.00 gestiegen.

Was ist die größte Einnahmequelle von Bioventus Inc?

Am 2026Q1 erzielte das Geschäft mit Pain Treatments für Bioventus Inc den höchsten Umsatz in Höhe von 279.06M, was 49.12% des Gesamtumsatzes entspricht.